AddedRisk Factors
Managed care organizations and other third-party payors try to negotiate the pricing of medical services and products to control their costs. Managed care organizations and pharmacy benefit managers typically develop formularies to reduce their
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, the success of our fulfillment arrangements with Walgreen Co. and our dermatology cash-pay prescription program is subject to various risks, including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, pharmacy benefit managers, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws. Any failure of these arrangements to achieve market acceptance or any non-compliance with applicable laws could have a material adverse effect on our business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
▪tariffs imposed (or proposed to be imposed) by the U.S. (including in respect of the countries and sectors in which we do business) and counter-tariffs or other retaliatory measures imposed (or that may be imposed) on the U.S. by other countries, disruptions to global supply chains and the potential results of these developments;
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
During 2025, the Trump administration imposed increased and new tariffs on various countries. Additional tariffs and other protective measures are being investigated and may also be imposed. Counter-tariffs and other retaliatory measures have been threatened and imposed on the United States by various countries. The United States has negotiated trade agreements with some countries on tariff matters and negotiations with others are ongoing. These tariffs and counter-tariffs have had and may continue to have an impact on some of the countries in and with which we do business and some of the sectors in which we are engaged. While we believe we will be able to mitigate some of the impact of these tariffs, counter-tariffs and other trade restrictions through the use of certain levers and other actions, these measures may not be successful in mitigating all of the impacts of these tariffs and other trade matters.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedRisk Factors
•the ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the B+L Separation and the costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the ongoing legal proceedings, investigations, and inquiries respecting certain of our historical distribution, marketing, pricing, disclosure and accounting practices;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Certain contracts used in our business may need to be replaced in connection with any B+L Separation and failure to obtain such replacement contracts could increase our expenses or otherwise adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
In connection with any B+L Separation, we may be required to replace certain shared contracts. It is possible that, in connection with the replacement process, some parties may seek more favorable contractual terms from us. If we are unable to obtain such replacement contracts, the loss of these contracts could increase our expenses or otherwise materially adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
We are involved in a number of other legal and governmental proceedings and may be involved in additional litigation in the future. Some of these proceedings are complex and extended and occupy the resources of our management and employees. Some of these proceedings are also costly to prosecute or defend and may involve substantial awards or damages payable by us if not found in our favor. We may also be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such proceedings. Defending against or settling such claims and any unfavorable legal decisions, settlements or orders could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For more information regarding legal proceedings, see Note 20, “LEGAL PROCEEDINGS” to our audited Consolidated Financial Statements.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
For example, the pharmaceutical industry, including our Company, has been the focus of both private payor and governmental concern regarding pricing of pharmaceutical products. Related actions, including Congressional and other governmental investigations and litigation, are costly and time-consuming, and adverse resolution of such actions or changes in our business practices, such as our approach to the pricing of our pharmaceutical products, could adversely affect our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
defend against charges that we infringed, misappropriated or otherwise violated patents or the intellectual property or proprietary rights of third parties. Third parties may also request a preliminary or permanent injunction from a court of law to prevent us from marketing a product. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. If we are found to infringe, misappropriate or otherwise violate the intellectual property rights of others, we could lose our right to develop, manufacture or sell products, including our generic products, or could be required to pay monetary damages or royalties to license proprietary rights from third parties, which could be substantial and include treble damages and attorneys’ fees, if we are found to willfully infringe any intellectual property rights of others. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Any of the foregoing events could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
We face an inherent business risk of exposure to significant product liability and other claims in the event that the use of our products caused, or is alleged to have caused, adverse effects. These product liability proceedings may be costly to prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Furthermore, our products may cause, or may appear to cause, adverse side effects (including death) or potentially dangerous drug interactions that we may not learn about or understand fully until the drug has been administered to patients for some time. The withdrawal of a product following complaints and/or incurring significant costs, including the requirement to
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, the AR Facility Agreement (as defined below) contains affirmative and negative covenants applicable primarily to the borrower subsidiaries thereunder, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions, and engaging in any business other than as set forth in the AR Facility Agreement. Other debt instruments we may enter into in the future may contain additional restrictions and covenants.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Any significant leadership change or senior management transition involves inherent risks, and any future changes to our management that may occur during the transition could cause significant disruption to the Company and its operations. The
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
failure to adequately manage succession of senior management and other key personnel or the failure of key employees to successfully transition into new roles could cause further disruption to our business. In addition, changes in senior management may create uncertainty among investors, employees, business partners and others concerning the Company’s future direction and performance. Any disruption in our operations or adverse impacts from such uncertainty could have a material adverse effect on our business, financial condition, cash flows and results of operations.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedRisk Factors
If an event of default is not cured or is not otherwise waived, a majority of lenders in principal amount under our 2022 Amended 2025 Credit Agreement or the trustee or holders of at least 25% in principal amount of a series of our senior notes may accelerate the maturity of the related debt under these agreements, foreclose upon any collateral securing the debt and terminate any commitments to lend, any of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our common shares and/or debt securities to decline.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Potential difficulties that may be encountered in the integration process include the following: integrating personnel, operations and systems, while maintaining focus on selling and promoting existing and newly-acquired products; coordinating geographically dispersed organizations; distracting management and employees from operations; retaining existing customers and attracting new customers; maintaining the business relationships the acquired company has established, including with health care providers; and managing inefficiencies associated with integrating the operations of Bausch + Lomb and the acquired business, product or other assets. newly-
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we have successfully settled or otherwise resolved a number of legacy legal proceedings, investigations and inquiries relating to, among other things, our disclosure and accounting practices and our former relationship with Philidor, Philidor Rx Services LLC (“Philidor”), including the securities class action litigation matters in both the U.S. and Canada, the investigation by the SEC, the investigation order from the Autorité des marches financiers (our principal securities regulator in Canada) and certain derivative lawsuits, we are currently still the subject of a number of other ongoing legal proceedings and investigations and inquiries by governmental agencies, proceedings, including, but not limited to, a number of pending securities litigations, the following: allegations of which relate to, among other things, allegedly false and misleading statements by the Company and/or failures to disclose information about our business and prospects.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result of the ongoing conflict between Russia and Ukraine, the current and any future responses by the global community to such conflict and any counter responses by the Russian government or other entities or individuals, and the potential expansion of the conflict to other countries, we may continue to experience an adverse impact on our business and operations in this region, as well as on our business and operations generally, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline. business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Moreover, if If we are not able to adequately recognize and respond to such developments and governmental, investor and social stakeholder expectations, including expectations of lenders, investors and other stakeholders relating with respect to ESG matters, we may miss corporate opportunities for the Company, become subject to additional regulatory, legal or regulatory risk, face increased social, investor or other scrutiny, incur unexpected costs or experience damage to the reputation of the Company or its various brands with governments, customers, employees, investors, third parties and the communities in which we operate, in each case that could have a material adverse effect on our business, financial condition, cash flows and results of operations business and could cause the market value of our common shares and/or debt securities to decline.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
A failure by us to retain, motivate and recruit executives and other key employees or the unanticipated loss of the services of any of these executives or key employees for any reason, whether temporary or permanent, could create disruptions in our business, could cause concerns and instability for management and employees, current and potential customers, credit rating agencies and other third parties with whom we do business and our shareholders and debt holders and could cause concern regarding our ability to execute our business strategy or to manage operations in the manner previously conducted and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. conducted.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
We cannot predict what these changes may involve or the timing of any such changes and how they will impact our product sales, revenue, business, financial condition, cash flows or results of operations, but any such changes could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. operations.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Given the international scope of our operations, any of the above factors, including sanctions, export controls, tariffs, including potential new tariffs and/or retaliatory tariffs that have been discussed in recent months, tariffs, trade wars and other governmental actions, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our business, financial condition, cash flows and results of operations are business is subject to risks arising from the international scope of our operations, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
These measures and these proposed measures legislation, and legislation, if implemented, any actions taken by the Company in response, could lead to impairment of certain of our intangible assets which could be significant, and/or could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. cash flows.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, geopolitical instability (such as the imposition of and adverse changes to U.S. duty, tariff and other trade protection measures, measures and countermeasures against the United States being taken in retaliation for the same, the ongoing conflict between Russia and Ukraine and Ukraine, the ongoing conflicts and unrest in the Middle East) East, and tensions between the U.S. and other members of NATO and related sanctions and other measures could continue to have significant ramifications on global financial markets, including volatility in the U.S. and global financial markets.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, as a result of any failure to retain, or loss of, any executives or key employees, we may experience increased costs in order to identify and recruit a suitable replacement in a timely manner (and, even if we are able to hire a qualified successor, the search process and transition period may be difficult to manage and result in additional periods of uncertainty), which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. uncertainty).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The B+L Separation, which may include a distribution of all or a portion of our remaining equity interest in Bausch + Lomb to our shareholders, is could be subject to further challenge, which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
For example, the allegations about the activities of Philidor and our former relationship with Philidor have resulted in a number of investigations, inquiries and legal proceedings against us, which have damaged and may further damage our reputation and result in damages, fines, penalties or administrative sanctions against the Company and/or certain of our officers.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we perform below our forecasted levels and the actions referenced above are not effective, we would may fail to comply with our financial maintenance covenant. covenants.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
These statements are based upon the current expectations and beliefs of management. Readers are cautioned that actual results may vary from those in the forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions relating to: (i) our ability to execute our business strategy, business plans and operational efficiency initiatives; (ii) demand for, competitive positioning of and pricing for our current and anticipated products and our ability to achieve expected revenues, margins and expense levels; (iii) the successful development, regulatory approval, manufacture and timing of launches and commercialization of pipeline and other products; (iv) the completion, timing, integration and expected benefits of acquisitions and other strategic transactions (including the acquisition of DURECT Corporation (“DURECT”)) and the planned separation of our eye health business consisting of our Bausch + Lomb global Vision Care, Surgical and Pharmaceuticals businesses on anticipated terms, timing and costs; (v) the scope, duration and financial and operational impact of product quality matters; (vi) the continued availability and performance of key third‑party distribution, fulfillment and other arrangements and the stability of global supply chains; (vii) the continuation of patent protection and regulatory exclusivity for key products; (viii) the expected impacts of the Inflation Reduction Act (“IRA”), and the selection by the Centers for Medicare & Medicaid Services (“CMS”) of Xifaxan® for the second round of negotiation under the drug price negotiation program for initial price applicability in 2027 and the results thereof, and other healthcare reform measures and our ability to mitigate the impact thereof; (ix) our ability to generate cash flows and access liquidity to meet working capital needs, satisfy debt maturities as they become due, reduce debt levels and comply with financial and other covenants under our financing arrangements; (x) the expected scope and impact of tariffs, counter‑tariffs and other trade restrictions and the effectiveness of mitigation actions; (xi) macroeconomic and geopolitical conditions (including inflation, recessionary pressures, foreign currency exchange rates and interest rates), changes in tax laws and related guidance (including legislation referred to as the One Big Beautiful Bill Act (the “OBBBA”) and Organisation for Economic Co-operation and Development (“OECD”) related measures); (xii) the expected outcomes of litigation and other contingencies; and (xiii) the factors described under Item 1A. “Risk Factors” in this Form 10-K and in the Company’s other filings with the U.S. Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators (the “CSA”).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On April 8, 2025, the Company and its indirect wholly-owned subsidiary, 1261229 B.C. Ltd., a company incorporated under the laws of British Columbia, Canada (“126NumberCo”), closed a series of transactions (the “April 2025 Refinancing Transactions”) whereby it: (i) entered into a credit agreement which provides for new senior secured credit facilities (the “2025 Credit Agreement”) consisting of a five-year senior secured revolving credit facility in an amount of $500 million due April 8, 2030 (the “2030 Revolving Credit Facility”) and a $3,000 million 5.5-year senior secured term loan B facility due October 8, 2030 (the “2030 Term Loan B Facility”, and together with the 2030 Revolving Credit Facility, the “2025 Senior Secured Credit Facilities”) and (ii) issued $4,400 million aggregate principal amount of 10.00% senior secured notes due April 15, 2032 (the “2032 Senior Secured Notes”).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The proceeds from the April 2025 Refinancing Transactions were used: (i) to repay in full and terminate the Company’s term loan facility (the “February 2027 Term Loan B Facility”), (ii) to redeem certain senior secured notes, certain unsecured notes and the 9.00% Senior Secured Notes due 2028 (the “9.00% Intermediate Holdco Secured Notes”), (iii) to pay related fees, premiums and expenses and (iv) for general corporate purposes.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The April 2025 Refinancing Transactions reduced our short-term cash requirements for debt service by extending approximately $6,870 million in aggregate debt maturities from the years 2025 through 2028 to the years 2030 through 2032.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The December 2025 Exchange reduced our short-term cash requirements for debt service by extending approximately $1,600 million in aggregate debt maturities from the year 2028 to the year 2032.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Defined terms used above but not defined in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are defined and discussed in Note 10, “FINANCING ARRANGEMENTS” to our audited Consolidated Financial Statements.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On June 26, 2025, certain of Bausch + Lomb’s subsidiaries, Bausch + Lomb Netherlands B.V. and Bausch & Lomb Incorporated (the “B+L Issuers”), issued €675 million aggregate principal amount of Senior Secured Floating Rate Notes due January 2031 (the “B+L January 2031 Senior Secured Notes”). The proceeds from the B+L January 2031 Senior Secured Notes, along with the proceeds of the B+L January 2031 Term Loan B Facility, were used by Bausch + Lomb to: (i) repay in full, borrowings under the B+L May 2027 Revolving Credit Facility, (ii) refinance, in full, its outstanding term loans due 2027 and (iii) pay related fees and expenses.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The B+L 2025 Refinancing Activity reduced our short-term cash requirements for debt service by extending approximately $2,800 million in aggregate debt maturities from the year 2027 to the year 2031.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The April 2025 Refinancing Transactions, August 2025 Repurchase Activity, December 2025 Exchange, repayment of the AR Credit Facility, B+L 2025 Refinancing Activity and B+L January 2031 Refinancing Term Facility provide us more flexibility to operate and allow us to more effectively allocate capital to initiatives that will strengthen our products and brands.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
•Larsucosterol - In September 2025, we completed the acquisition of DURECT. Larsucosterol, DURECT’s lead drug candidate, has the potential to be the first FDA approved therapeutic option for AH patients. The FDA has granted a Breakthrough Therapy designation for this drug. A registrational Phase 3 program to evaluate the safety and efficacy of Larsucosterol for the treatment of patients with severe AH is planned to start in early 2026.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
•Rifaximin - In January 2026, we received the results for the double-blind Phase 3 clinical trials for two global clinical programs evaluating our rifaximin soluble solid dispersion (“SSD”) formulation of rifaximin, known as rifaximin SSD-40IR, as part of our RED-C clinical trial program (“RED-C”). These trials were aimed to assess the drug’s ability to delay the first occurrence of overt hepatic encephalopathy (“OHE”) in patients with early decompensated liver cirrhosis. While safe and well-tolerated, both clinical trials failed to achieve their primary endpoint.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
•Thermage® FLX - A non-invasive, FDA-cleared skin tightening treatment designed to reduce wrinkles and rhytids, including those on the upper and lower eyelids. It uses radiofrequency energy to stimulate collagen production, resulting in tighter, more contoured skin. The device received Health Canada approval in April 2025.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedMD&A
•The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan® product line currently represent approximately 85% of the Salix segment revenues.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The Diversified segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) dermatology products, (iii) generic pharmaceutical products and (iv) dentistry products.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We continue to execute on a multi-year plan designed to transform and bring out value in our Company, which includes focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management. We believe that these and other actions we have taken have helped to focus our operations and improve our capital structure.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Borrowings under the AR Credit Facility are in U.S. dollars and bear interest at a rate per annum equal to the sum of the one month term SOFR plus 6.65%. The Company is required to pay commitment fees of 0.75% multiplied by the lesser of: (i) the unfunded portion of the lenders’ commitments or (ii) 50% of the total lenders’ commitments.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
During 2022, we improved our capital structure and reduced the aggregate principal amount of our debt obligations by approximately $3,800 million, as we: (i) utilized the net proceeds from the B+L IPO which closed on May 10, 2022, to make repayments of debt, (ii) reduced our debt through open market repurchases of debt with a principal value of approximately $927 million for approximately $550 million, (iii) extended the maturities of our debt through refinancing and (iv) completed an exchange offer which reduced the outstanding principal balance of our debt by $2,469 million by exchanging $5,594 million of aggregate principal value of existing unsecured senior notes (the “Existing Unsecured Senior Notes”) for newly issued secured notes with an aggregate principal balance of $3,125 million (the “2022 Exchange”).
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
The B+L IPO, 2022 Notes Issuance and Credit Agreement Refinancing - In connection with the B+L IPO, we completed a series of transactions in support of our commitment to improve our liquidity, reduce our leverage and better capitalize the two business entities post-separation. These transactions included:
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•On February 10, 2022, the Company issued $1,000 million aggregate principal amount of 6.125% Senior Secured Notes due February 2027.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The B+L IPO closed, with aggregate net proceeds (including the partial exercise of the over-allotment option by the underwriters), after deducting underwriting commissions, of approximately $675 million.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The Company entered into the 2022 Amended Credit Agreement as defined and discussed in Note 10, “FINANCING ARRANGEMENTS” to our audited Consolidated Financial Statements. The 2022 Amended Credit Agreement consists of term loans of $2,500 million and a revolving credit facility of $975 million.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
Years Ended December 31, Change (in millions) 2025 2024 2023 2022 2023 2024 to 2024 2022 to 2023 2025 Net loss income (loss) $ 120 $ (72) $ (611) $ (212) $ 539 $ (399) 192 Adjustments to reconcile Net loss income (loss) to net cash provided by operating activities 1,499 1,662 2,225 (120) (563) 2,345 (163) Cash provided by (used in) operating activities before changes in operating assets and liabilities 1,619 1,590 1,614 (332) (24) 1,946 29 Changes in operating assets and liabilities (219) 7 (582) (396) 589 (186) (226) Net cash provided by (used in) operating activities 1,400 1,597 1,032 (728) 565 1,760 (197) Net cash used in investing activities (595) (454) (2,145) (303) 1,691 (1,842) (141) Net cash (used in) provided by used in financing activities (742) (868) 1,475 (474) (2,343) 1,949 126 Effect of exchange rate changes on cash and cash equivalents 61 (36) 9 (23) (45) 32 97 Net increase (decrease) in cash, cash equivalents, equivalents and restricted cash and other settlement deposits 124 239 371 (1,528) (132) 1,899 (115) Cash, cash equivalents, equivalents and restricted cash and other settlement deposits, cash, beginning of year 1,201 962 591 2,119 371 (1,528) 239 Cash, cash equivalents, equivalents and restricted cash and other settlement deposits, cash, end of year $ 1,325 $ 1,201 $ 962 $ 591 $ 239 $ 371 124
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
(i) the repurchase and retirement of certain outstanding senior unsecured notes with aggregate par value of $555 million for approximately $530 million, (ii) $400 million of repayments under the B+L Revolving Credit Facility, (iii) $295 million of contractual interest payments on the 2022 Secured Notes allocated to the reduction of the recorded premiums, (iv) $155 million of amortization on the Term Loan B Facilities and (v) repayments of $50 million under our AR Credit Facility and $30 million under our 2027 Revolving Credit Facility, partially offset by the Issuance of long-term debt of $661 million, representing $396 million from the B+L May 2027 Incremental Term Loan B Facility, borrowings of $235 million under the B+L Revolving Credit Facility and $30 million under the 2027 Revolving Credit Facility.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
On a non-consolidated basis, the non-guarantor subsidiaries with respect to the Senior Unsecured Notes and Secured Notes (other than the 2032 Senior Secured Notes) had total assets of $16,252 $26,030 million and $16,306 $16,252 million and total liabilities of $8,982 $17,438 million and $8,575 $8,982 million as of December 31, 2024 2025 and 2023, and 2024, respectively, revenues of $5,914 million and $5,509 million for 2025 and $4,653 2024, respectively, operating loss of $26 million for 2025 and operating income of $110 million and $119 million for 2024 and 2023, respectively. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
(in millions) 2025 2024 2023 Acquired IPR&D costs $ 114 $ 18 Litigation and other matters $ matters, net of insurance recoveries and restitutions 61 220 $ (53) Acquired in-process research and development Acquisition-related transaction costs 18 — 9 4 Net gain on sale of assets (6) (10) (3) Acquisition-related contingent consideration (36) 15 59 Acquisition-related transaction costs 4 24 Other, net — 1 Other expense, net $ 142 $ 247 $ 28
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
During January 2024 and May 2024, through a series of transactions In August 2025, we repurchased and retired our outstanding senior unsecured notes 9.25% Senior Unsecured Notes due April 2026 with an aggregate par value of $555 million for approximately $530 $602 million using cash on hand. hand, for an aggregate cost of approximately $601 million (the “August 2025 Repurchase Activity”).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
In connection with At the time of our announcement of the B+L Separation, we have emphasized that it is important that the post-separation entities be appropriately capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
On a non-consolidated basis, the non-guarantor subsidiaries with respect to the 2032 Senior Secured Notes had total assets of $16,252 million and $16,306 $16,595 million and total liabilities of $8,982 million and $8,575 $8,171 million as of December 31, 2024 and 2023, 2025 and revenues and operating loss of $5,509 $5,914 million and $4,653 million and operating income of $110 million and $119 $26 million for 2024 and 2023, 2025, respectively.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
(i) a decrease an increase in volumes net realized pricing of $54 $82 million, primarily in our Neurology and Dermatology businesses Neuroscience business and (ii) the $17 million impact from the discontinuation of divestitures and discontinuations of $21 million, certain non-promoted products which negatively impacted our revenues in 2024, primarily in our Dermatology and Generics businesses.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by operating activities was $1,400 million and $1,597 million for 2025 and 2024, respectively, a decrease of $197 million and includes reductions for interest payments of $1,674 $1,534 million and $1,533 $1,379 million and payments (net of refunds received) for income taxes of $163 million and $61 million for 2025 and $237 million for 2024 and 2023, 2024, respectively.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
(“we”, “us”, “our”, the “Company” or “Bausch Health”) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (“GI”), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and aesthetic medical devices and, through our approximately 88% ownership of Bausch + Lomb Corporation (“Bausch + Lomb” or “B+L”), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
(i) an increase in volumes of $348 $301 million across all the Bausch + Lomb businesses, (ii) the favorable impact of foreign currencies of $58 million and (iii) incremental sales attributable to acquisitions of $293 $16 million, primarily within the Pharmaceuticals business and (iii) an increase in net realized pricing of $81 million, primarily driven by the Vision Care Surgical business, partially offset by:
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
We continue to invest in expanding our presence in key markets, including are also broadening the reach of our DTC campaigns in the U.S., the expansion of Thermage® FLX which was approved by China’s National Medical Products Administration as a medical device in January 2024, 2024 and granted medical device license clearance by Health Canada in April 2025, and the strengthening of our sales force in the U.S. North America, Asia and Europe.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
The original premium recorded on the 2022 Secured Notes was $1,835 million, which will be has been reduced as contractual interest payments are made on the 2022 Secured Notes.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new